+39 06 72596393

fismed@uniroma2.it

    Narges Nasrollahi

    Studenti Visitatori e Alumni

    Email

    narges.nasrollahi@gmail.com

    Biografia

    Narges Nasrollahi è ricercatrice in Neuroscienze Molecolari, specializzata nella somministrazione mirata mediata da FUS e nelle nanobolle attraverso la BBB. È titolare di un brevetto per la sintesi di nanobolle contenenti farmaci biogenerici per la somministrazione mirata con FUS, registrato come PCT.

    La sua ricerca innovativa ha ottenuto un significativo sostegno finanziario, tra cui una borsa di studio sabbatica a Roma da parte dell’Organizzazione iraniana MSRT, oltre a molteplici sovvenzioni da parte dell’Iran Nanotechnology Innovation Council (INIC), della Vicepresidenza iraniana per la scienza e la tecnologia (ISTI), dell’Iran National Science Foundation (INSF), dell’Iran National Innovation Fund (INIF) e del National Institute of Genetic Engineering and Biotechnology (NIGEB).

    Gli eccezionali contributi di Narges l’hanno portata a ricevere il primo premio all’evento Phoenix organizzato dalla National Elites Foundation. Il suo progetto si è distinto tra 500 proposte concorrenti, facendole guadagnare un premio di 20.000 dollari. Inoltre, nel 2024 è stata premiata come studente modello al NIGEB.

    Profili

    Created with Fabric.js 4.6.0

    Scopus

    Pubmed

    LinkedIn

    Laboratori

    UltraSuoni (TheraFus)

    Ultime 5 pubblicazioni (Scopus)

    opensearch:totalResults = 3
    opensearch:startIndex = 0
    opensearch:itemsPerPage = 3
    @role = request
    @searchTerms = AU-ID(57226827565) OR AU-ID(58976441100)
    @startPage = 0

    @_fa = true
    @ref = self
    @href = https://api.elsevier.com/content/search/scopus?start=0&count=25&query=AU-ID%2857226827565%29+OR+AU-ID%2858976441100%29&apiKey=6ae70c855c11cca26b94ca23c22dcbcf
    @type = application/json

    @_fa = true
    @ref = first
    @href = https://api.elsevier.com/content/search/scopus?start=0&count=25&query=AU-ID%2857226827565%29+OR+AU-ID%2858976441100%29&apiKey=6ae70c855c11cca26b94ca23c22dcbcf
    @type = application/json


    inizio

    @_fa = true

    @_fa = true
    @ref = self
    @href = https://api.elsevier.com/content/abstract/scopus_id/85189797956

    @_fa = true
    @ref = author-affiliation
    @href = https://api.elsevier.com/content/abstract/scopus_id/85189797956?field=author,affiliation

    @_fa = true
    @ref = scopus
    @href = https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85189797956&origin=inward

    @_fa = true
    @ref = scopus-citedby
    @href = https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85189797956&origin=inward

    The impact of hUC MSC–derived exosome-nanoliposome hybrids on α-synuclein fibrillation and neurotoxicity; Science Advances; April 2024; DOI: 10.1126/sciadv.adl3406
    prism:url = https://api.elsevier.com/content/abstract/scopus_id/85189797956
    dc:identifier = SCOPUS_ID:85189797956
    eid = 2-s2.0-85189797956
    dc:creator = Aliakbari F.
    prism:publicationName = Science Advances
    prism:issn =
    prism:eIssn = 23752548
    prism:volume = 10
    prism:issueIdentifier = 14
    prism:pageRange =
    prism:coverDate = 2024-04-05
    prism:coverDisplayDate = April 2024
    prism:doi = 10.1126/sciadv.adl3406
    citedby-count = 3

    @_fa = true
    affilname = Robarts Research Institute
    affiliation-city = London
    affiliation-country = Canada

    @_fa = true
    affilname = National Institute for Genetic Engineering and Biotechnology Iran
    affiliation-city = Tehran
    affiliation-country = Iran

    pubmed-id = 38569030
    prism:aggregationType = Journal
    subtype = ar
    subtypeDescription = Article
    article-number = eadl3406
    source-id = 21100457028
    openaccess = 1
    openaccessFlag = true
    value:

    $ = all

    $ = publisherfullgold

    $ = repository

    $ = repositoryvor

    value:

    $ = All Open Access

    $ = Gold

    $ = Green

    prism:isbn:

    @_fa =
    $ =

    pii =

    inizio

    @_fa = true

    @_fa = true
    @ref = self
    @href = https://api.elsevier.com/content/abstract/scopus_id/85143232428

    @_fa = true
    @ref = author-affiliation
    @href = https://api.elsevier.com/content/abstract/scopus_id/85143232428?field=author,affiliation

    @_fa = true
    @ref = scopus
    @href = https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85143232428&origin=inward

    @_fa = true
    @ref = scopus-citedby
    @href = https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85143232428&origin=inward

    Viral and non-viral gene therapy using 3D (bio)printing; Journal of Gene Medicine; December 2022; DOI: 10.1002/jgm.3458
    prism:url = https://api.elsevier.com/content/abstract/scopus_id/85143232428
    dc:identifier = SCOPUS_ID:85143232428
    eid = 2-s2.0-85143232428
    dc:creator = Jahangiri S.
    prism:publicationName = Journal of Gene Medicine
    prism:issn = 1099498X
    prism:eIssn = 15212254
    prism:volume = 24
    prism:issueIdentifier = 12
    prism:pageRange =
    prism:coverDate = 2022-12-01
    prism:coverDisplayDate = December 2022
    prism:doi = 10.1002/jgm.3458
    citedby-count = 8

    @_fa = true
    affilname = Université de Montréal, Faculté de Médecine
    affiliation-city = Montreal
    affiliation-country = Canada

    @_fa = true
    affilname = Centre Hospitalier de L'Université de Montréal
    affiliation-city = Montreal
    affiliation-country = Canada

    pubmed-id = 36279107
    prism:aggregationType = Journal
    subtype = re
    subtypeDescription = Review
    article-number = e3458
    source-id = 18922
    openaccess = 0
    openaccessFlag = false
    value:

    $ =

    value:

    $ =

    prism:isbn:

    @_fa =
    $ =

    pii =

    inizio

    @_fa = true

    @_fa = true
    @ref = self
    @href = https://api.elsevier.com/content/abstract/scopus_id/85112803548

    @_fa = true
    @ref = author-affiliation
    @href = https://api.elsevier.com/content/abstract/scopus_id/85112803548?field=author,affiliation

    @_fa = true
    @ref = scopus
    @href = https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85112803548&origin=inward

    @_fa = true
    @ref = scopus-citedby
    @href = https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85112803548&origin=inward

    Prevascularized Micro-/Nano-Sized Spheroid/Bead Aggregates for Vascular Tissue Engineering; Nano-Micro Letters; December 2021; DOI: 10.1007/s40820-021-00697-1
    prism:url = https://api.elsevier.com/content/abstract/scopus_id/85112803548
    dc:identifier = SCOPUS_ID:85112803548
    eid = 2-s2.0-85112803548
    dc:creator = Rahimnejad M.
    prism:publicationName = Nano-Micro Letters
    prism:issn = 23116706
    prism:eIssn = 21505551
    prism:volume = 13
    prism:issueIdentifier = 1
    prism:pageRange =
    prism:coverDate = 2021-12-01
    prism:coverDisplayDate = December 2021
    prism:doi = 10.1007/s40820-021-00697-1
    citedby-count = 45

    @_fa = true
    affilname = Centre Hospitalier de L'Université de Montréal
    affiliation-city = Montreal
    affiliation-country = Canada

    @_fa = true
    affilname = University of Montreal
    affiliation-city = Montreal
    affiliation-country = Canada

    pubmed-id =
    prism:aggregationType = Journal
    subtype = ar
    subtypeDescription = Article
    article-number = 182
    source-id = 21100203115
    openaccess = 1
    openaccessFlag = true
    value:

    $ = all

    $ = publisherfullgold

    $ = repository

    $ = repositoryvor

    value:

    $ = All Open Access

    $ = Gold

    $ = Green

    prism:isbn:

    @_fa =
    $ =

    pii =

    Ultime 5 pubblicazioni PubMed

    • The impact of hUC MSC-derived exosome-nanoliposome hybrids on α-synuclein fibrillation and neurotoxicity

      Amyloid aggregation of α-synuclein (αSN) protein amplifies the pathogenesis of neurodegenerative diseases (NDs) such as Parkinson's disease (PD). Consequently, blocking aggregation or redirecting self-assembly to less toxic aggregates could be therapeutic. Here, we improve brain-specific nanocarriers using a hybrid of exosomes (Ex) from human umbilical cord mesenchymal stem cells (hUC MSCs) and nanoliposomes containing baicalein (Ex-NLP-Ba) and oleuropein (Ex-NLP-Ole). The hybrids contained both...

    • Viral and non-viral gene therapy using 3D (bio)printing

      The overall success in launching discovered drugs is tightly restricted to the high rate of late-stage failures, which ultimately inhibits the distribution of medicines in markets. As a result, it is imperative that methods reliably predict the effectiveness and, more critically, the toxicity of medicine early in the drug development process before clinical trials be continuously innovated. We must stay up to date with the fast appearance of new infections and diseases by rapidly developing the...

    • Prevascularized Micro-/Nano-Sized Spheroid/Bead Aggregates for Vascular Tissue Engineering

      Efficient strategies to promote microvascularization in vascular tissue engineering, a central priority in regenerative medicine, are still scarce; nano- and micro-sized aggregates and spheres or beads harboring primitive microvascular beds are promising methods in vascular tissue engineering. Capillaries are the smallest type and in numerous blood vessels, which are distributed densely in cardiovascular system. To mimic this microvascular network, specific cell components and proangiogenic...

    CONTATTI

    Orario Segreteria

    • Lun-Ven 09:00-15:00

    collegamenti

    Facebook Twitter Instagram

    Sito creato da An:Ca © 2025 Università di Roma Tor Vergata P.I. 02133971008 – C.F. 80213750583